Volume 12 (2025): Issue 1

Clinical profile and outcome of children with haemophilia A: The Royal Hospital, Oman’s experience

Open Access | | Creative Commons Attribution NonCommercial NoDerivatives
Anood AlRawahi ORCID iD
Ibrahim AlGaithi ORCID iD
Fatma Al Riyami ORCID iD
Maather Al Abri ORCID iD
Hajer Al Shukaili ORCID iD
Abdulhakim Al Rawahi ORCID iD

Abstract

Abstract Background

Data on clinical characteristics and bleeding outcome of Omani children with haemophilia A (HA) is limited. This study aims to describe the clinical profile and outcome of Omani children with HA at the Royal Hospital from 2006 to 2019.

Methods

This is a retrospective study including all Omani children (< 13 years) with HA at the Royal Hospital. Data included age at presentation, factor VIII (FVIII) level, treatment, complications, and bleeding episodes.

Results

Forty-four males were included; mean age was 1 year ± 1.7 years at presentation. Mean period of follow-up was 7.9 ± 3.6 years. The most common complaints at presentation were muscle bleeds (29.5%) and post-circumcision bleeding (11.4%). Two (4.5%) had mild HA, 29 (66%) had moderate HA, and 13 (29.5%) had severe HA. Twenty-eight (63.6%) were on regular prophylaxis, ten (22.7%) developed at least one target joint, and six (13.6%) developed FVIII inhibitors. The mean annualised bleeding rate was 1.8 ± 2.3, 4.6 ± 0.4, and 4.6 ± 8.6 for the persons with mild, moderate, and severe HA, respectively.

Conclusion

The clinical phenotype of Omani children is milder compared to other studies but with similar clinical outcomes.

Article

View Full Article

References

  • 1. Kaneda M, Kawasaki R, Matsumoto N, et al. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost 2021; 19: 2938–46. doi: https://doi.org/10.1111/jth.15506.
  • 2. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801–9. doi: https://doi.org/10.1016/S0140-6736(03)13405-8.
  • 3. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27:179–84. doi: https://doi.org/10.1016/j.blre.2013.06.002.
  • 4. Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost 2011; 37: 737–44. doi: https://doi.org/10.1055/s-0031-1297164.
  • 5. Sidonio RF. “A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH”: Reply to comment. J Thromb Haemost 2022; 20: 1745–6. doi: https://doi.org/10.1111/jth.15726.
  • 6. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: A meta-analytic approach using national registries. Ann Intern Med 2019; 171:540–6. doi: https://doi.org/10.7326/M19-1208.
  • 7. Kulkarni R, Soucie JM, Lusher J, et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project. Haemophilia 2009; 15: 1281–90. doi: https://doi.org/10.1111/j.1365-2516.2009.02074.x.
  • 8. Tagliaferri A, Di Perna C, Riccardi F, et al. The natural history of mild haemophilia: a 30-year single centre experience. Haemophilia 2012; 18: 166–74. doi: https://doi.org/10.1111/j.1365-2516.2011.02617.x.
  • 9. Balak DMW, Gouw SC, Plug I, et al. Prenatal diagnosis for haemophilia: a nationwide survey among female carriers in the Netherlands. Haemophilia 2012; 18: 584–92. doi: https://doi.org/10.1111/j.1365-2516.2011.02742.x.
  • 10. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895–902. doi: https://doi.org/10.1111/j.1538-7836.2010.03962.x.
  • 11. Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev 2013; 34: 289–94. doi: https://doi.org/10.1542/pir.34-7-289.
  • 12. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44. doi: https://doi.org/10.1056/NEJMoa067659.
  • 13. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700–10. doi: https://doi.org/10.1111/j.1538-7836.2011.04214.x.
  • 14. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121:4046–55. https://doi.org/10.1182/blood-2012-09-457036.
  • 15. Regling K, Callaghan MU, Sidonio R. Managing severe hemophilia A in children: pharmacotherapeutic options. Pediatr Health Med Ther 2022; 13: 27–35. doi: https://doi.org/10.2147/PHMT.S293246.
  • 16. Negrier C, Young G, Abdul Karim F, et al. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia 2016; 22: 507–13. doi: https://doi.org/10.1111/hae.12902.
  • 17. Oudat R, Al-Maharmeh M, Al-Ghrayeb R, Ogeilat T, Mustafa MK. Prevalence of FVIII inhibitors among children with hemophilia A: Experience at the Jordanian Royal Medical Services. Med Arch Sarajevo Bosnia Herzeg 2020; 74: 187–90. doi: https://doi.org/10.5455/medarh.2020.74.187-190.
  • 18. Trimble SR, Parker CS, Grant AM, Soucie JM, Reyes N. Assessing emerging infectious threats to blood safety for the blood disorders community. Am J Prev Med 2010; 38: S468–474. doi: https://doi.org/10.1016/j.amepre.2009.12.019.
  • 19. Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost 2001; 85: 577–9. doi: https://doi.org/10.1055/s-0037-1615636.
  • 20. Benson G, Auerswald G, Dolan G, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus 2018; 16: 535–44. doi: https://doi.org/10.2450/2017.0150-17.
  • 21. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016; 388: 187–97. doi: https://doi.org/10.1016/S0140-6736(15)01123-X.
  • 22. Pezeshkpoor B, Oldenburg J, Pavlova A. Insights into the molecular genetic of hemophilia A and hemophilia B: The relevance of genetic testing in routine clinical practice. Hamostaseologie 2022; 42: 390–9. doi: https://doi.org/10.1055/a-1945-9429.
  • 23. Owaidah T, Momen AA, Alzahrani H, et al. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program. Medicine (Baltimore) 2017; 96: e5456. doi: https://doi.org/10.1097/MD.0000000000005456.
  • 24. Kadhim KAR, Al-Lami FH, Baldawi KH. Epidemiological profile of hemophilia in Baghdad-Iraq. Inquiry 2019; 56: 46958019845280. doi: https://doi.org/10.1177/0046958019845280.
  • 25. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125: 2038–44. doi: https://doi.org/10.1182/blood-2015-01-528414.
  • 26. Rehill AM, McCluskey S, O’Donnell JS, et al. Heterogeneity in bleeding tendency and arthropathy development in individuals with hemophilia. Semin Thromb Hemost 2021; 47: 183–91. doi: https://doi.org/10.1055/s-0041-1723769.
  • 27. Gringeri A, von Mackensen S, Auerswald G, et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia 2004; 10 Suppl 1: 26–33. doi: https://doi.org/10.1111/j.1355-0691.2004.00876.x.
  • 28. Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972–2001. Blood 2004; 104: 3494–500. doi: https://doi.org/10.1182/blood-2004-05-2008.
  • 29. Di Minno MND, Ambrosino P, Franchini M, Coppola A, Di Minno G. Arthropathy in patients with moderate hemophilia a: a systematic review of the literature. Semin Thromb Hemost 2013; 39: 723–31. doi: https://doi.org/10.1055/s-0033-1354422.
  • 30. Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost 2021; 19: 2112–21. doi: https://doi.org/10.1111/jth.15444.
  • 31. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica 2020; 105: 545–53. doi: https://doi.org/10.3324/haematol.2019.232132.
  • 32. Nazir H, khanbashi L, Wali Y, et al. Screening for inhibitor development and its risk factors in patients with severe haemophilia a in Oman. Hematol Transfus Int J 2018; 6: 87–90. doi: https://doi.org/10.15406/htij.2018.06.00159.
  • 33. Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606–12. doi: https://doi.org/10.1111/j.1365-2516.2007.01518.x.

PDF Download

Download PDF

Open in full-page viewer

Authors

  • Anood AlRawahi

    ORCID iD
    Pediatrics Program, Oman Medical Speciality Board, Muscat, Oman

  • Ibrahim AlGaithi

    ORCID iD
    Ibrahim.alghaithi@gmail.com
    Consultant, Department of Pediatric Hematology/Oncology, Royal Hospital, Ministry of Health, Muscat, Oman .

  • Fatma Al Riyami

    ORCID iD
    Medical Officer, Ministry of Health, Muscat, Oman

  • Maather Al Abri

    ORCID iD
    General Surgery Program, Oman Medical Specialty Board, Muscat, Oman

  • Hajer Al Shukaili

    ORCID iD
    General Foundation Program, Oman Medical Specialty Board, Muscat, Oman

  • Abdulhakim Al Rawahi

    ORCID iD
    Head of Research, Oman Medical Specialty Board, Muscat, Oman